The future of peptide supplementation may soon take a dramatic leap forward as Digital Emeralds (Australia), Hy-bio Pharmaceutical (Shenzhen), and JY-Med Technology (Shenzhen) collaborate on the development of innovative oral peptide gummies designed for wellness and longevity. If successful, the project could reshape how consumers access peptide-based products by replacing traditional injectable formats with convenient oral gummies while utilizing advanced drug-delivery technologies that protect delicate peptide molecules from destruction inside the digestive system. Peptides such as Tirzepatide, Liraglutide, Retatrutide, CJC-1295, Ipamorelin, Tesamorelin, Sermorelin, BPC-157, TB-500, GHK-Cu, Epitalon, MOTS-c, AOD-9604, PT-141 (Bremelanotide), Melanotan II, Semax, Selank, KPV, Thymosin Alpha-1 (TA1), LL-37, Dihexa, SS-31, and DSIP will all soon be available as gummies in a variety of flavors.
Image Credit: Thailand Wellness News
The collaboration aims to harness cutting-edge pharmaceutical science to solve one of the greatest challenges in peptide delivery—ensuring that fragile peptide molecules survive the harsh environment of the stomach and are successfully absorbed into the bloodstream. This Wellness News report examines how emerging technologies inspired by the success of oral semaglutide could pave the way for a new generation of peptide gummies that offer convenience without sacrificing effectiveness. While the technology remains under development, industry experts believe it represents one of the most promising advances in wellness delivery systems in recent years.
Inspired by the Success of Oral Semaglutide
For many years, peptides have primarily been administered through injections because digestive enzymes and stomach acids rapidly break them down before they can enter the bloodstream. This has limited their widespread use among consumers seeking convenient wellness products.
However, the pharmaceutical industry demonstrated that oral peptide delivery is possible with the introduction of oral semaglutide, marketed as Rybelsus. The achievement was considered a major scientific breakthrough because it successfully enabled a peptide to survive the stomach long enough for a small percentage to be absorbed into circulation.
The same scientific principles are now inspiring researchers developing next-generation peptide gummies. Rather than relying solely on injections, the goal is to formulate oral products capable of protecting peptide ingredients during digestion while encouraging absorption in the stomach.
A Strategic Partnership
Digital Emeralds (Thailand) a branding and marketing company that is also into AI and healthcare has partnered with Hy-bio Pharmaceutical and JY-Med Technology, both based in Shenzhen, to explore advanced oral peptide technologies aimed at the wellness and longevity market. Digital Emeralds holds the patents for the new process which was developed by researchers from India and Japan and the project has been financed by investors from Dubai, California and New York. Refinement of the patented process and tweaking along with actual production and initial clinical trials will be done in China.
Hy-bio Pharmaceutical is recognized for manufacturing commercially approved peptide active pharmaceutical ingredients (APIs) and maintains official FDA Drug Master Files for several peptide products. This pharmaceutical manufacturing capability provides an important foundation for developing high-quality peptide formulations.
Meanwhile, JY-Med Technology contributes expertise in peptide research and pharmaceutical innovation, complementing the partnership’s objective of producing effective oral peptide products suitable for commercial wellness applications.
The collaboration intends to combine pharmaceutical manufacturing standards with advanced formulation science and innovative delivery technologies to create gummies that consumers may find significantly easier and more appealing than injectable alternatives.
Solving the Biggest Challenge
The greatest obstacle facing oral peptide delivery has always been biology.
Once swallowed, peptides encounter an extremely hostile digestive environment. Stomach acid, digestive enzymes such as pepsin, and the body’s natural protective barriers rapidly destroy most peptide molecules before they can reach the bloodstream.
Even if some molecules survive digestion, they still face another challenge: crossing the stomach lining or intestinal wall to enter systemic circulation.
Without specialized delivery systems, virtually all orally consumed peptides are broken down into inactive fragments before absorption occurs.
The Role of SNAC Technology
Scientists overcame much of this problem through the development of SNAC, formally known as sodium N-(8-(2-hydroxybenzoyl) amino) caprylate.
SNAC functions as an absorption enhancer rather than as the active drug itself. When combined with semaglutide, it creates a temporary microenvironment around the dissolving tablet that dramatically improves the chances of peptide survival.
The enhancer performs several important functions simultaneously.
First, it temporarily raises the local pH surrounding the dissolving tablet. This localized buffering effect reduces the activity of digestive enzymes such as pepsin, helping prevent rapid degradation of the peptide.
Second, SNAC assists in separating semaglutide molecules that naturally cluster together into larger complexes. Individual peptide molecules, known as monomers, are considerably easier to absorb than large molecular clusters.
Third, SNAC temporarily interacts with the stomach cell membranes, increasing their fluidity and allowing peptides to pass directly through stomach cells into the bloodstream via transcellular transport.
Importantly, this increased permeability is temporary and reversible. Within minutes, stomach cells return to their normal protective state.
Absorption Still Remains Challenging
Despite this remarkable pharmaceutical engineering, oral peptide delivery remains relatively inefficient.
Published research on oral semaglutide indicates that only a very small percentage of the swallowed dose ultimately reaches systemic circulation. Estimates generally place absolute bioavailability at approximately 0.4% to 2%, meaning that between 98% and 99% of the administered peptide is never absorbed.
This low absorption explains why oral semaglutide must be taken under carefully controlled conditions, including an empty stomach, minimal water intake, and waiting before consuming food or additional medications.
Although these limitations exist, even modest improvements in oral bioavailability have been sufficient to produce clinically meaningful therapeutic effects.
Applying Similar Science to Gummies
The collaboration involving Digital Emeralds (Thailand), Hy-bio Pharmaceutical, and JY-Med Technology seeks to adapt comparable scientific principles for peptide gummies intended for wellness and longevity applications.
Researchers working with Digital Emeralds had successfully developed a new process that has been patented which combines nanotechnology, proprietary absorption enhancers resembling SNAC, and additional chemical technologies designed to shield peptide molecules from digestive destruction.
The objective is to allow peptides to remain intact long enough for meaningful absorption within the stomach rather than relying primarily on intestinal uptake.
Nanotechnology may also contribute by encapsulating peptide molecules inside microscopic protective carriers that resist acidic degradation while releasing their contents only when optimal absorption conditions have been established.
These approaches significantly improve convenience while maintaining meaningful peptide delivery.
Image Credit: Thailand Wellness News
Beyond SNAC: New Generation Absorption Enhancers
The new process does not rely on SNAC as several alternative absorption technologies have emerged over recent years.
One example is sodium caprylate (C8), which is used in oral peptide formulations employing transient permeation enhancer (TPE) technology. Unlike SNAC, these systems typically bypass the stomach using enteric coatings before temporarily opening tight junctions between intestinal cells to facilitate peptide absorption.
Another promising enhancer is sodium caprate (C10), a surfactant derived from capric acid. C10 has demonstrated strong potential for increasing intestinal permeability and is being evaluated in numerous oral peptide development programs.
Researchers had also investigated hybrid formulations that combine SNAC with C10. The concept is straightforward: SNAC encourages peptides to move directly through stomach cells, while C10 temporarily opens pathways between intestinal cells. Together, the dual mechanisms could improve absorption beyond current levels.
Although these technologies remain under active investigation, the actual technology that the tea has developed and is using has already been tested in animal models and is now being utilized in coming production with minor “tweaking” expected before human trials.
Implications for the Wellness Industry
Once these oral peptide gummies debut, the implications for the wellness industry could be considerable.
Consumers who are reluctant to use injections may become more willing to incorporate peptide-based wellness products into their daily routines once administration becomes as simple as consuming a gummy.
Improved convenience could also support better long-term compliance, particularly among individuals interested in healthy aging, metabolic wellness, body composition management, recovery, and longevity-focused supplementation.
The technology may also create entirely new product categories while expanding consumer access beyond clinical settings.
However extensive formulation research and tweaking, manufacturing validation, regulatory review, and clinical evaluation remain essential before these new peptide gummy products can establish efficacy, consistency, and safety.
Looking Ahead
The collaboration between Digital Emeralds (Thailand), Hy-bio Pharmaceutical, and JY-Med Technology highlights how advances originally developed for pharmaceutical medicines may increasingly influence the wellness sector. By combining pharmaceutical-grade peptide manufacturing with sophisticated delivery technologies including nanotechnology, absorption enhancers, and protective formulations, the partners hope to overcome one of peptide science’s most persistent challenges.
Whether peptide gummies ultimately become a mainstream wellness product will depend on continued scientific validation, manufacturing quality, regulatory acceptance, and real-world performance. Even so, the direction of research suggests that oral peptide delivery is progressing rapidly beyond conventional tablets and may soon enter entirely new consumer-friendly formats. Once these innovations fulfill their promise, injectable-only peptide administration may eventually become less common for selected wellness applications, potentially opening the door to a more accessible generation of longevity-focused products that combine convenience with advanced pharmaceutical science.
For the latest in peptides research, keep on logging to Thailand Wellness News.
